OncoBEAM™ BRAF

  • The OncoBEAM™ BRAF test is a bead-based digital PCR approach (also called BEAMing Digital PCR) detecting two mutations found at codon 600 of the BRAF oncogene.
  • Mutations covered:
    V600E, V600K

Documents

All
  • All
  • Brochure
Documents

V-raf murine sarcoma viral oncogene homolog B1 (BRAF) is a member of the RAF family of protein kinases playing a key role within the MAPK signaling pathway and is frequently mutated in human cancers  (1).
As it displays aberrant activity in tumor entities for which no or only limited effective therapies are available, BRAF is a highly attractive target for targeted therapies. Indeed, BRAF inhibitors in patients with malignant melanoma are changing the treatment paradigm of this highly lethal disease (2). In addition, BRAF mutation status has been shown to be predictive for response to anti-EGFR therapy in colorecal cancer patients (3).

 

 

* FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

BACK TO LIST

Mutations

Mutations

Clinical Relevance

Clinical Relevance

Cancer Relevance

  • Colorectal cancer
  • Melanoma
  • Papilliary thyroid cancer

 

Drug Relevance

  • Vemurafenib (Zelboraf®)
  • Novel small molecule inhibitors (RAF, MEK)
  • Anti-EGFR therapies including cetuximab (Erbitux®) and panitumumab (Vectibix®)
Test Details

Test Details

Turn around time

< 10 days

Sample Requirements

  • Serum/Plasma
    0.5 ml – 4 ml
  • FFPE/Frozen Tissue
    3 sections at 5 μm
References

References

  1. Rajagopalan H et al. (2002) Nature 418(6901):934.
  2. Bhatia S et al. (2012) J Natl Compr Canc Netw. 10(3):403-12
  3. Molinari F et al. (2011) Clin Cancer Res. 17:4901-4914
Create Pdf